Dianthus Therapeutics
DNTH | NASDAQ
$89.55
-$2.26 (-2.46%)
At close: Nov 16, 2026, 4:00 PM ET
$89.02
-$0.53 (-0.59%)
After-hours:
Nov 16, 2026, 7:51 PM ET
Dianthus Therapeutics Company Profile
Company profile explainedCompany Profile
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Marino Garcia | President, Chief Executive Officer & Director |
| Kristina Maximenko | Chief People Officer |
| Adam Veness | Senior Vice President, General Counsel & Secretary |
| Edward G. Carr | Senior VP & Chief Accounting Officer |
| Jennifer Davis Ruff | Vice President and Head of Investor Relations & Corporate Affairs. |
| Judson Taylor | Senior Vice President & Head of Technical Operations |
| Rashieda Gluck | Head of Clinical Development Operations |
| Ryan Savitz | Executive VP, CFO, Chief Business Officer & Treasurer |
| Scott Nogi | Head of Business Operations |
| Simrat Randhawa | Executive Vice President and Head of R&D |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | S-3ASR | Automatic shelf registration statement of securiti... |
| Sep 03, 2026 | 4 | Filing |
| Aug 19, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 11, 2026 | 4 | Filing |
| Aug 11, 2026 | 4 | Filing |
Dianthus Therapeutics
| Country | United States |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 92 |
| CEO | Marino Garcia |
Contact Details
7 Times Square New York,
New York 10036 United States
Stock Details
| Ticker Symbol | DNTH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001690585 |
| CUSIP Number | 252828108 |
| ISIN Number | US2528281080 |
| SIC Code | 2834 |
Recent News
- 17 hours ago / seekingalpha.comDianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript
- 8 days ago / zacks.comWall Street Analysts See a 61.23% Upside in Dianthus Therapeutics, Inc. (DNTH): Can the Stock Really Move This High?
- 12 days ago / zacks.comDianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates
- 14 days ago / globenewswire.comDianthus Therapeutics to Participate in Five Investor Conferences During November
- 1 month ago / globenewswire.comDianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharma
- 2 months ago / globenewswire.comDianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
- 2 months ago / seekingalpha.comDianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
- 3 months ago / globenewswire.comDianthus Therapeutics to Participate in Three Investor Conferences During September
- 3 months ago / seekingalpha.comDianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case
- 3 months ago / zacks.comDianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
Add to Watchlist
Select watchlists to add or remove DNTH